Twist Bioscience insider files Form 144 for 619 shares after vesting

Rhea-AI Filing Summary

Twist Bioscience (TWST) filed a Form 144 disclosing a proposed sale of 619 common shares with an aggregate market value of $16,071.84, to be sold approximately on 08/21/2025 on NASDAQ. The shares were acquired on 08/20/2025 upon restricted stock vesting and were issued as compensation. The filer reports prior sales by the same person, Paula Green, totaling 3,174 shares across five transactions between 05/21/2025 and 08/04/2025, producing gross proceeds of $97,059.51. The filer certifies they are unaware of any undisclosed material adverse information about the issuer.

Positive

• Transparent disclosure of the proposed sale date, share count, market value, acquisition date, and nature of acquisition (restricted stock vesting).
• Detailed history of prior insider sales is provided, including dates, amounts, and gross proceeds, aiding investor transparency.

Negative

• Insider selling activity: the filer (Paula Green) sold 3,174 shares in the prior three months and plans to sell an additional 619 shares, which could be viewed negatively by some investors.

Insights

Securities Analyst

TL;DR: Routine insider sale following restricted stock vesting; modest size relative to typical equity floats.

This Form 144 reports a planned sale of 619 shares resulting from restricted stock vesting and notes multiple recent sales by the same insider totaling 3,174 shares and $97,059.51 in proceeds. The sale is scheduled for NASDAQ and appears to be compensation-driven rather than a cash-funded sale. For investors, this is a transparent disclosure of insider liquidity but does not, by itself, indicate material company developments.

Corporate Governance Expert

TL;DR: Disclosure aligns with compliance expectations; repeated insider sales warrant routine monitoring.

The filing meets Rule 144 disclosure norms by identifying the source as restricted stock vesting and providing specific dates and amounts. Recurrent sales by the same individual are documented, which is useful for governance oversight and monitoring insider trading patterns. No statement in the filing indicates undisclosed adverse information, per the filer's certification.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	619	16071.84	60360925	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2025	Restricted Stock Vesting	Issuer			619	08/20/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Paula Green 681 Gateway Blvd South San Francisco CA 94080	Common	05/21/2025	632	18800.36
Paula Green 681 Gateway Blvd South San Francisco CA 94080	Common	06/06/2025	853	27082.41
Paula Green 681 Gateway Blvd South San Francisco CA 94080	Common	06/20/2025	292	10440.37
Paula Green 681 Gateway Blvd South San Francisco CA 94080	Common	07/02/2025	142	5139.42
Paula Green 681 Gateway Blvd South San Francisco CA 94080	Common	08/04/2025	1255	35596.95

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TWST Form 144 disclose about the upcoming sale?

The filing discloses a proposed sale of 619 common shares valued at $16,071.84, to be sold approximately on 08/21/2025 on NASDAQ.

How were the 619 TWST shares acquired?

The shares were acquired on 08/20/2025 by restricted stock vesting and the payment nature is listed as compensation.

Has the filer sold TWST shares recently?

Yes. Paula Green sold 3,174 shares across five transactions from 05/21/2025 to 08/04/2025, generating gross proceeds of $97,059.51.

On which exchange will the TWST shares be sold?

The planned sale is to occur on NASDAQ.

Does the filer claim undisclosed adverse information about Twist Bioscience?

The filer certifies by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.